Business Context and Reporting Period
Filing mismatch: The requested company is OnKure Therapeutics, Inc., but the supplied Form 10-Q is for Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company developing mavodelpar for rare genetic mitochondrial diseases. The filing covers the quarter and six months ended June 30, 2023, and was filed August 10, 2023.
Reneo has no approved products and has not generated product revenue. Its lead and only product candidate is mavodelpar, being developed for primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD).
Financial Metrics
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $14.4 million | $25.4 million |
| General and administrative expense | $6.6 million | $11.8 million |
| Total operating expenses | $21.0 million | $37.2 million |
| Other income | $1.5 million | $2.5 million |
| Net loss | $19.5 million | $34.6 million |
| Net loss per share | $0.65 | $1.25 |
| Net cash used in operating activities | Not separately disclosed | $25.2 million |
At June 30, 2023, cash and cash equivalents were $9.1 million, short-term investments were $133.6 million, and total liquidity was approximately $142.7 million. Total assets were $148.0 million and stockholders’ equity was $132.5 million.
Total liabilities were $15.5 million, including $13.7 million of current liabilities and $1.2 million of operating lease liabilities. The filing does not disclose traditional borrowings or debt financing.
Six-month investing cash outflows were $50.5 million, primarily from purchases of short-term investments. Financing cash inflows were $64.8 million, including $58.9 million from a public offering, $4.7 million from a private placement, and $1.0 million from the ATM facility. Cash and cash equivalents declined by $10.8 million during the six months.
Material Changes Versus Prior Comparable Period
- Quarterly R&D expense increased $6.3 million, or approximately 77%, to $14.4 million; six-month R&D expense increased $8.0 million, or approximately 46%, to $25.4 million. The increases primarily reflected clinical, regulatory, manufacturing, personnel, and medical-affairs spending.
- Quarterly G&A expense increased $2.3 million, or approximately 54%, to $6.6 million; six-month G&A expense increased $3.7 million, or approximately 46%, to $11.8 million, driven by additional personnel, facilities, and commercial-development activities.
- Quarterly net loss increased $7.2 million to $19.5 million; six-month net loss increased $9.3 million to $34.6 million.
- Other income increased substantially due to higher interest rates and larger short-term investment balances.
- Liquidity increased from approximately $101.2 million at December 31, 2022 to approximately $142.7 million at June 30, 2023, primarily due to equity financing proceeds.
- Shares outstanding increased from 24.7 million at December 31, 2022 to 33.8 million at June 30, 2023, reflecting dilution from equity offerings and other issuances.
Guidance, Outlook, Risks, and Unusual Items
- Management expects topline results from the pivotal STRIDE Phase 2b trial in the fourth quarter of 2023 and potential submission of a U.S. NDA for mavodelpar in the first half of 2024.
- The STRIDE trial enrolled 213 patients, above the target of 200. The company also reported more than 130 patients enrolled in the STRIDE AHEAD open-label extension study.
- Management expects R&D and G&A expenses to increase substantially as clinical development, regulatory activities, commercial preparation, and sales and marketing planning progress.
- Although management expects existing liquidity to fund operations beyond a potential NDA submission, it concluded that substantial doubt exists about the company’s ability to continue as a going concern for more than one year from the filing date, primarily because of anticipated commercial and sales-and-marketing expenditures.
- Management expects to seek additional equity or debt financing, credit facilities, collaborations, strategic alliances, licensing arrangements, or other funding. It may defer certain commercial activities if additional capital is not obtained.
- The company depends entirely on the successful development and approval of mavodelpar. Key risks include clinical-trial failure or delay, regulatory rejection, safety findings, limited rare-disease market size, manufacturing and supply constraints, third-party CRO dependence, intellectual-property risks, and the need to build commercial capabilities.
- The vTv license agreement requires potential future development and regulatory milestone payments of up to $64.5 million, sales-based milestones of up to $30.0 million, and tiered royalties on net sales. No milestones were recorded during the reported periods.
- A $7.5 million CEO performance award was valued at $876,000 at June 30, 2023; $847,000 of fair-value expense was recognized during the six months.
- In April 2023, the company entered into but ultimately did not pursue a non-binding term sheet for up to $100 million of structured royalty financing.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is Reneo Pharmaceuticals, Inc., not OnKure Therapeutics, Inc.
- Verify STRIDE topline results, regulatory interactions, and whether an NDA was submitted in the anticipated 2024 timeframe.
- Assess the going-concern disclosure and the timing, terms, and dilution implications of any required capital raise.
- Review cash burn relative to the approximately $142.7 million of liquidity and expected increases in commercial spending.
- Evaluate mavodelpar’s clinical efficacy, safety profile, trial endpoints, and the risk that regulatory authorities require additional studies.
- Review potential vTv milestone, royalty, and license-termination obligations, as well as the durability of related intellectual-property protection.
- Consider dilution from the May 2023 offerings, the remaining approximately $18.8 million ATM capacity, stock options, restricted stock units, and future equity issuances.